Navigation Links
ImQuest Awarded SBIR Grant to Define the Mechanism of Action of Their Lead Anti-HIV Therapeutic Compound IQP-0410
Date:7/9/2008

FREDERICK, Md., July 9 /PRNewswire/ -- ImQuest Life Sciences announced today the successful acquisition of funding from the National Institutes of Health to define the mechanism of action of their dual-acting pyrimidinedione HIV inhibitor IQP-0410. The objective of this one-year Small Business Innovative Research (SBIR) award will allow ImQuest scientist to further understand how the pyrimidinediones inhibit the replication of HIV. IQP-0410 has been determined to primarily inhibit the function of the virion reverse transcriptase, but the clinical candidate also possesses a novel second mechanism of action which functions to prevent the entry of HIV into human target cells, extends the range of action of the compound to HIV-2 and results in enhanced levels of activity against multi-drug resistant virus strains. The SBIR award will allow ImQuest to better define the putative entry inhibition target, thus allowing the eventual development of an entirely new class of virus entry inhibitors. Dr. Robert W. Buckheit, Jr., Dr. Todd Parsley, and Ms. Tracy Hartman lead the research project.

"We are extremely pleased to receive this NIH SBIR award," said Dr. Buckheit. "IQP-0410 represents a completely novel dual-acting chemotype for development as an HIV therapeutic and ImQuest hopes to more completely understand how this compound inhibits HIV replication, initiate our planned clinical trials, and work on the development of a new generation of even more potent entry inhibitors that will provide HIV-infected individuals with yet another therapeutic option to fight their disease."

ImQuest plans to submit an IND to the Food and Drug Administration in the third quarter of 2008 in order to initiate Phase 1 human clinical trials with IQP-0410. Preclinical pharmacology and toxicology results have been highly encouraging that the compound will present a new highly potent and less toxic alternative for primary and salvage therapies in HIV-infected individuals. The pyrimidinedione series is being developed for use as both HIV therapeutics and topical microbicides.

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in early stage drug development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective therapeutic and microbicide development services to the biotechnology and pharmaceutical industry.

Robert W. Buckheit, Jr., Ph.D.

EVP, Chief Scientific Officer

rbuckheit@imquest.com


'/>"/>
SOURCE ImQuest Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. Mirus Bio Awarded Grants & Contracts of Over $5 Million
3. ICx Awarded $1.5 M Contract by Department of Homeland Security for Development of Next Generation Bio Aerosol Systems
4. ViPS Awarded Enterprise Systems Development (ESD) Contract By CMS
5. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
6. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
7. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
8. Isis Awarded $1.5 Million NIH Grant to Improve Chemical Properties of RNAi-Based Therapeutics
9. Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million
10. Implicit Awarded US $16.3 Million U.S. Government Contract to Develop Immunomodulatory Drug for Biodefense Threats
11. BIO-key(R) Awarded Contract to Deploy Incident Reporting System for Littleton, CO Police Department
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. Stock-Callers.com has initiated coverage on the following equities: ... (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing their ...
(Date:6/23/2016)... India , June 23, 2016 ... media market research report to its pharmaceuticals section ... profiles, product details and much more. ... spread across 151 pages, profiling 15 companies and ... available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
Breaking Biology Technology:
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
Breaking Biology News(10 mins):